

Newly identified risk factors for MRSA carriage in The Netherlands

W. S. N. Lekkerkerk

A. Haenen

M. A. B. van der Sande

T. Leenstra

S. de Greeff

A. Timen

A. Tjon-a-Tsien

J. H. Richardus

N. van de Sande-Bruinsma

M. C. Vos

PLoS One, November 2017

ABSTRACT

Objectives

To elucidate new risk factors for MRSA carriers without known risk factors (MRSA of unknown origin; MUO). These MUO carriers are neither pre-emptively screened nor isolated as normally dictated by the Dutch Search & Destroy policy, thus resulting in policy failure.

Methods

We performed a prospective case control study to determine risk factors for MUO acquisition/carriage (Dutch Trial Register: NTR2041). Cases were MUO carriers reported by participating medical microbiological laboratories to the RIVM from September 1st 2011 until September 1st 2013. Controls were randomly selected from the community during this period.

Results

Significant risk factors for MUO in logistic multivariate analysis were antibiotic use in the last twelve months, aOR 8.1 (5.6–11.7), screened as contact in a contact tracing but not detected as a MRSA carrier at that time, aOR 4.3 (2.1–8.8), having at least one foreign parent, aOR 2.4 (1.4–3.9) and receiving ambulatory care, aOR 2.3 (1.4–3.7). Our found risk factors explained 83% of the MUO carriage.

Conclusions

Identifying new risk factors for MRSA carriers remains crucial for countries that apply a targeted screening approach as a Search and Destroy policy or as vertical infection prevention measure.

INTRODUCTION

In The Netherlands MRSA prevalence is low, measured at 0.12% at hospital admission in 2005–2007¹ and 0.8% in Dutch outpatients in the Dutch-German border region in 2012.² Among *S.aureus* blood-cultures the MRSA prevalence was 1.0% (24/2,386).³ To keep MRSA prevalence low, prudent use of antibiotics is instigated and a Search and Destroy policy (S&D) is in place. S&D consists of screening of defined risk patients (Table 1) at hospital admission, and by pre-emptive isolation of them pending the screening results.⁴ Colonized patients and healthcare workers are treated with strict treatment regimens to eradicate the carriage of MRSA.⁴ One of the revisions on MRSA risk groups, was due to the discovery of livestock-associated MRSA with sequence type 398 (LA-MRSA ST398) in The Netherlands.⁵ The risk groups for S&D were subsequently updated with pig and veal calf farmers. In 2016, LA-MRSA accounted for 26% (892/3,478) of MRSA isolates.³ Apart from the discovery of LA-MRSA, it appeared that the proportion of reported MRSA without known risk factors, thus not defined as risk patients, became substantial. In 2008–2009, 25% (1350/5545) of all MRSA were reported as MRSA without known risk factors.⁶ In 2016, this has increased to 38% (810/2,121).³ The MRSA without known risk factors were named MRSA of Unknown Origin or MUO. MUO are per definition unexpected and are mostly detected in clinical samples. However, in screening samples on MRSA, MUO can be detected as well. This is the case when the found MRSA genotype does not match the MRSA genotype of the index person.⁶ We started a nation-wide study to explore the risks and causes of MUO, so the defined risk groups in S&D policy can be updated and unnoticed dissemination of MRSA in healthcare settings and the community can be stopped. In this paper, we report the results from our prospective case control study to determine the risk factors for carriage of MUO.

METHODS

MRSA surveillance

In the Netherlands, all MRSA are detected either through active surveillance screening or in a clinical sample and are mandatorily sent to the Dutch National Institute for Public Health and the Environment (RIVM). Yearly, around 3,000 isolates are submitted to the RIVM.⁷ Along with the isolate, risk factors for MRSA carriage, as defined in the MRSA guideline by the Dutch Working party on Infection Prevention (WIP), are reported to the RIVM by standard questionnaire.^{8, 9} Any person detected with MRSA and reported with one or more risk factors as described in this WIP guideline is defined as MRSA of Known Origin (MKO). Any person detected with MRSA lacking these risk factors, is defined as MRSA of Unknown Origin (MUO).

Table 1 – Risk categories in the Dutch WIP guideline on MRSA

January 2007 (updated: March 2008) ⁸		December 2012 ⁷	
Patients		Healthcare workers	
Category 1	Category 2	Category 1	Category 2
<ul style="list-style-type: none"> - Proven carrier status of MRSA 	<ul style="list-style-type: none"> - Nursed < 2 months > 24h in a foreign hospital - Nursed < 2 months < 24h in a foreign hospital with the following risk factors at arrival in a Dutch hospital: operation, infection, catheter or drains present - Patient from department (hospital or nursing home) with an ongoing MRSA outbreak - Adopted children regularly hospitalized or visiting the hospital - Foreign patient at dialysis unit - Share a room with unexpected MRSA carrier - After MRSA eradication therapy but before follow-up culture-sets are taken - Contact with live pigs or veal calves 	<ul style="list-style-type: none"> - Proven carrier status of MRSA - Follow-up after MRSA eradication therapy (3 follow-up culture-sets) 	<ul style="list-style-type: none"> - Proven carrier status of MRSA - Follow-up after MRSA eradication therapy (3 follow-up culture-sets) - Undergoes MRSA eradication treatment
Category 2	Category 2	Category 2	Category 2
<ul style="list-style-type: none"> - Nursed < 2 months > 24h in a foreign hospital - Nursed < 2 months < 24h in a foreign hospital with the following risk factors at arrival in a Dutch hospital: operation, infection, catheter or drains present - Patient from department (hospital or nursing home) with an ongoing MRSA outbreak - Adopted children regularly hospitalized or visiting the hospital - Foreign patient at dialysis unit - Share a room with unexpected MRSA carrier - After MRSA eradication therapy but before follow-up culture-sets are taken - Contact with live pigs or veal calves 	<ul style="list-style-type: none"> - Unprotected contact with MRSA carrier - Hospitalized < 2 months ago in a foreign hospital, were operated abroad, received a drain or catheter, were intubated, have skin lesions or possible infectious sources such as abscesses or furuncles. 	<ul style="list-style-type: none"> - Proven carrier status of MRSA - Follow-up after MRSA eradication therapy (3 follow-up culture-sets) 	<ul style="list-style-type: none"> - Nursed < 2 months > 24h in a foreign care facility - Nursed < 2 months < 24h in a foreign care facility with at least one of the following risk factors: operation abroad, chronic infection or persistent skin lesions, presence of abscesses or furuncles at hospitalization in the Netherlands.

Table 1 – Risk categories in the Dutch WIP guideline on MRSA (continued)

January 2007 (updated: March 2008) ^a		December 2012 ⁷	
Patients		Healthcare workers	
Category 3	Category 3	Category 3	Category 3
<ul style="list-style-type: none"> - Dutch dialysis patients dialyzed abroad - First year after MRSA eradication therapy with MRSA negative follow-up culture-sets - Nursed > 2 months in foreign hospital with persistent skin infections or risk factors 	<ul style="list-style-type: none"> - Protected contact with MRSA carriers < 2 months ago worked abroad >24h in a hospital or nursing home - First year after MRSA eradication therapy with MRSA negative follow-up culture-sets 	<ul style="list-style-type: none"> - Unprotected contact with MRSA positive HCW < 2 months ago - Dutch dialysis patients dialyzed abroad < 2 months ago - Nursed > 2 months in foreign hospital with persistent skin infections or risk factors - First year of follow-up after MRSA eradication therapy and the first three negative follow-up culture-sets - Persistent exposure with a negative MRSA test less than three months ago. 	<ul style="list-style-type: none"> - Persistent exposure with a negative MRSA test less than three months ago. - Unprotected contact with MRSA positive patient < 2 months ago inside or outside the hospital - < 2 months ago > 24h patient-related activities in a foreign care facility - Guided patients < 2 months ago from a foreign to a Dutch care facility without isolation precautions - Carrier with uncomplicated MRSA who was negative before the start of MRSA eradication therapy
Category 4	Category 4	Category 4	Category 4
<ul style="list-style-type: none"> - Nursed > 2 months ago in a foreign hospital without persistent skin lesions or risk factors - Stayed < 24h in a foreign hospital without risk factors or operations - On a department with MRSA where adequate precautions were taken - Negative follow-up culture-sets a year after MRSA eradication therapy ended 	<ul style="list-style-type: none"> - Successful MRSA eradication therapy > 1 year ago. Follow-up culture-sets remained MRSA negative - Negative follow-up culture-set after protected contact with MRSA carrier 	<ul style="list-style-type: none"> - None of the above categories applies 	<ul style="list-style-type: none"> - None of the above categories applies

HCW: Healthcare worker. For the trawling and case control questionnaires, the risk categories of the 2007-2008 WIP guideline were used. In 2015, the RIVM added as risk factor a refugee visiting a Dutch hospital who had been in a refugee camp less than two months before (category 2/3).

Trawling study

A trawling questionnaire was forwarded by Dutch Medical Microbiological Laboratories (MML) in 2010 to all MUO carriers reported to the RIVM in 2009. The retrospective trawling questionnaire was set-up to learn which risk factors could be involved with MUO to narrow and specify the number and kind of questions in the case control questionnaire, as well to choose the best control group for the case control study. To prevent recall bias, the maximum timespan for events in the past that had to be recalled by trawling study participants was limited to two years. To confirm that these MUO carriers were not misclassified MKO carriers, the questionnaire included questions on the described risk factors for MRSA in the Dutch WIP guideline on MRSA (Table 1). Furthermore, the questionnaire included questions on occupations, sports, leisure, social habits and lifestyles, and risk factors in other populations described in the literature. (PubMed at 01-01-2010, search keywords 'MRSA' and 'risk factor'). Excluded cases were non-responders, the deceased, potential cases that lacked an address or were misclassified as MKO for various reasons. Included cases were all MUO carriers not misclassified as MKO upon return of the questionnaire. Questionnaire data was analysed as described under 'statistics', and the results were interpreted to update the questionnaire and define the best controls.

Case control study

Study population

The study population consisted of patients detected with MRSA but without known risk factors (MUO) and population controls. The sample site and frequency of detection was not taken into account. In the Netherlands, persons detected with MRSA are all included in the national MRSA database, regardless of sample site, infection or indication for sampling. To determine the risk factors for MUO, we approached cases and controls with questionnaires (Supplementary list 1). Case control study participants who answered $\geq 95\%$ questions of the total of 43 questions and of whom informed consent was obtained, were rewarded with 25 euros and enrolled as case or control. To detect an odds ratio (OR) of 2 or higher with 80% power and an alpha of 0.05, we aimed to enrol 500 cases and 1,000 controls (1:2 case-control ratio), based on an estimated 700 MUO reported to the MRSA surveillance in two years (on a total of $\pm 3,000$ MRSA carriers reported per year).

Case definition

Potential cases were MRSA carriers, reported by the participating MML (medical microbiologist or infection prevention personnel) as MUO to the RIVM for the MRSA surveillance from September 1st, 2011 until September 1st, 2013. Before sending the questionnaire, assumed MUO cases were checked on the following exclusion criteria: death, lack of

address or misclassification (of a MKO as a MUO). Upon return of the questionnaire, we checked once more for misclassification. True MUO were included as case.

Control definition

Selecting the right controls was based on the results from the trawling study (see results below). The best control group was considered to be unmatched community controls. This choice was based on the fact that the MUO were selected from the RIVM database, which contained not only MRSA carriers detected at hospitals, but also those detected by general practitioners or in long-term care facilities. Furthermore, MUO carriers were shown to be a diverse group of carriers. The controls were randomly chosen from 60 Dutch municipalities from all over of The Netherlands. These 60 municipalities were a national representative subset of all 415 municipalities in The Netherlands, and contained large, middle and small municipalities.

Inclusion procedure

Every two weeks a printout was made in Microsoft Excel of the newly reported MUO to the RIVM. Questionnaires for MUO carriers were sent to participating MML (Supplementary table 1). The MML checked the carriers on exclusion criteria before forwarding the questionnaires to the MUO carriers. After three weeks, non-responders were once again approached by questionnaire or by telephone. Returned questionnaires of both cases and controls were checked to exclude any MKO carriers misclassified as MUO. Misclassifications were not included as cases. Controls were sent a questionnaire by mail. After three weeks non-responders were approached once more by mail or if possible by telephone. This study was approved by the medical ethical committee at the Erasmus MC and registered in the Dutch Trial Register under NTR2041. Written informed consent was requested from both cases as controls, before participating in this study by questionnaire. Data were aggregated and anonymized before analysis.

Statistics

Questionnaire data were analysed with SAS Enterprise Guide (version 4.2 by SAS Institute Inc., North Carolina, USA), using descriptive, univariate (2x2 tables and Fisher's Exact test) and multivariate analysis (multiple regression logit model, backward elimination with significance level of 0.05 to stay in the model, with and without dummy variables).

RESULTS

Trawling study

Of the reported 794 MUO to the MRSA surveillance, only 277 fulfilled inclusion criteria and could be approached by questionnaire through participating MML (Figure 1). Of these 37% (104/277) responded and all age groups were present. Of the 104 returned questionnaires, 22 were MKO, and thus misclassified as MUO and the remaining 82 were MUO.

Fifty-two percent (43/82) of MUO carriers were male and none of the MUO were health-care workers. Sixty-six percent (54/82) of MUO were patients detected in the hospital. However the other MUO carriers were detected by general practitioners or community-based healthcare institutions other than hospitals.




Figure 1 – Flowcharts for trawling and case control studies.

Case control study

Between September 1st 2011 and September 1st 2013 1,455 MUO were reported to the RIVM and 767 MUO were approached by questionnaire (Figure 1). The response rate among cases was 49% (376/767), that of controls 33% (667/2,000). Of the 376 returned questionnaires, 38% (144/376) of cases turned out to be MKO, thus misclassified as MUO, leaving 232 cases for analyses. None of these 232 cases were healthcare workers.

Comparing 232 cases with 667 controls, some risk factors, such as hospitalization of a household member, chronic disease, and carriage of ST398 MRSA without professional contact with pigs/veal calves or other farm animals, were significant in univariate analysis, but not in the final regression model (Table 2). Significant factors in the multivariate logistic regression model were antibiotic use in the last twelve months aOR 8.1 (95%CI 5.6–11.7), screened as contact in a contact tracing but not detected as a MRSA carrier at the time aOR 4.3 (95%CI 2.1–8.8), having at least one foreign parent aOR 2.4 (95%CI 1.4–3.9), and receiving ambulatory care aOR 2.3 (95%CI 1.4–3.7). The most frequently used antibiotics by cases and controls were β -Lactam-antibiotics. There was no significant difference ($p = 0.9$) between cases and controls for β -Lactam-antibiotics use in general, although there was a significant (OR 5.7; 95%CI 1.4–23.1) difference for the use of Amoxicillin/clavulanic acid (13.2% among cases (7/53) versus 2.6% (3/116) among controls). Among ambulatory care use, home care was the most common, and MUO carriers were significantly more exposed (OR 3.3; 95%CI 1.5–6.9) to it. Eighty-three percent of all MUO could be explained by the found independent risk factors in multiple regression model. (Table 3).

Table 2 – Multivariate logistic regression for MUO risk factors

Risk factor	MUO (n=232)	Controls (n=667)	p-value	aOR ^a	95%CI
ST398 but without professional contact with pigs/veal calves or other farm animals*	18	0	n.s.	1.8	(0.6-5.2)
Hospitalization within household ^b	84	157	n.s.	1.1	(0.7-1.7)
Chronic disease ²	85	135	n.s.	1.4	(0.9-2.0)
Antibiotic use in last 12 months	150	139	< 0.01	8.1	(5.6-11.7)
Screened as part of a contact tracing but not found to be a MRSA carrier at the time	24	23	< 0.01	4.3	(2.1-8.8)
At least one foreign parent	48	71	< 0.01	2.4	(1.4-3.9)
Ambulatory care received	55	66	< 0.01	2.2	(1.4-3.7)

aOR: adjusted Odds Ratios; CI: Confidence Interval;

* before 2012 only professional contact to pigs/veal calves was a risk factor. After 2012 any contact to pigs, veal calves and broiler chickens became a risk factor. But presence on a farm is not a risk factor per se, unless at the farm they have pigs, veal calves or broiler chickens.

^aLogistic regression model with backward elimination containing the following factors: no professional contact with pigs/veal calves or other farm animals, antibiotic use in the preceding 12 months, chronic disease, not detected with contact tracing, at least one foreign parent, hospitalization within the household and ambulatory care. The R^2 max of the model was 0.29, while the AUC was 0.79.

^bThese factors were univariate significant, as well as possible confounders for receiving ambulatory care.

Table 3 – Risk factors for MUO

Risk factors	MUO (%; n=232)
All cases with the risk factor:	
Antibiotic use in the last 12 months	150 (64.7)
Screened as part of a contact tracing but not found to be a MRSA carrier at the time	24 (10.3)
At least one foreign parent	48 (20.7)
Ambulatory care received	55 (23.7)
Number of cases that only have this one risk factor	
Antibiotic use in the last 12 months	52 (22.4)
Screened as part of a contact tracing but not found to be a MRSA carrier at the time	5 (2.2)
At least one foreign parent	8 (3.4)
Ambulatory care received	6 (2.6)
Number of cases that only have one risk factor	
Number of cases with a combination of 2 or more of the above risk factors	71 (30.6)
Total cases of MUO explained by these risk factors	121 (52.2)
Remaining unexplained MUO	192 (82.8)
	40 (17.2)

MUO carriers had a single risk factor in 30.6% (71/232) and had in 52.2% multiple risk factors. Among those MUO with a single significant risk factor, antibiotic use in last twelve months accounted for 22.4%, at least one foreign parent for 3.4%, ambulatory care received for 2.6%, and screened as part of a contact tracing but not found to be a MRSA carrier at the time for 2.2%.

DISCUSSION

We identified the following independent risk factors for MUO: antibiotic use in the preceding 12 months, receiving ambulatory care, and being screened for MRSA in contact tracing but not having been detected at the time. Travelling abroad was not a risk factor, although we found a significant association with having a foreign parent. In literature, antibiotic use in the last twelve months has been described before as risk factor for the general population; as a risk factor for MRSA carriage in children^{10, 11}, and within households where carriers were present¹². Also, a systematic review showed a association between antibiotic exposure to quinolones, glycopeptides, cephalosporins and beta-lactams and an increased risk of MRSA isolation in adults.^{13, 14} These former findings were confirmed by our study, as we found a significant difference in amoxicillin/clavulanic acid use between cases and controls. Greater use of amoxicillin/clavulanic acid may be due to more infections among MUO carriers compared to the controls. We cannot rule out this possibility as we did not measure the number of infections among MUO, since submission of an infection isolate to the MRSA database is preferred but not obliged. The Netherlands has

the lowest use of all antibiotics in the European Union. In 2013, 2015 and 2017, it was 10.8, 10.7 and 10.4 defined daily doses/1000 inhabitants/day respectively.^{3, 15}

Interestingly, having been screened as part of a contact tracing in the past, but not detected at that time, was a significant risk factor for MUO carriage. This is an important risk factor for countries with S&D policy, as this policy aims to identify all people at risk, including contacts. Explanations for this risk factor could be a too low sensitivity of MRSA culture, missing sampling sites, or when sampling occurs too early after exposure, and is not follow-upped with repeated sampling. For this reason it is also recommended to sample healthcare workers on start of their next duty instead of immediately after unprotected contact with a MRSA carrier. The current guideline indicates one set of samples from nose, throat, rectum and wounds when present. The guidelines assumes a sampling frequency of one set to be sufficient. There are no indications in the guideline on the timing of sampling of contacts after exposure when tracing MRSA contacts. Indeed, in our previous study we showed that carriage is not always detectable in each sample moment when sampling after MRSA eradication therapy to monitor MRSA recurrence.¹⁶ Further studies on reliability of contact tracing should be conducted, especially in regards to the number and sample sites of cultures when screening for contacts. Having at least one foreign parent, was also one of the significant risk factors. Possibly, an immigration background from countries with a higher MRSA prevalence may result in a higher exposure to MRSA by visiting or close contact within the family. Especially those countries with higher levels of CA-MRSA. This is in line with findings from Denmark which showed 40% of affected individuals CA-MRSA infections with certain CA-MRSA clones had a positive family history related to foreign regions where such clones were predominant.¹⁷ Furthermore, the MRSA prevalence among actively screened asylum seekers (refugees/immigrants) in The Netherlands was 9.7% (87/898).¹⁸ Similar to findings in Germany, but much higher than the prevalence in the general population at hospital admission.^{18, 19} In 2015, the RIVM added as risk factor a refugee visiting a Dutch hospital who had been in a refugee camp less than two months before (category 2/3).²⁰ It is possible that a limited understanding of the Dutch language prevented refugees from participating. If this is the case then our aOR for having at least one foreign parent, is an underestimation. Our national MRSA database currently contains *spa*, MLVA and PVL data. But this typing data, along with scarce epidemiological data, is currently not sufficient to link MUO to outbreaks abroad or transmission or sources occurring outside a Dutch health care centre. Furthermore, in this study we did not analyse the typing data, including PVL. As we did so in a previous study, and learned that PVL positive MRSA isolates were significantly larger among MUO than among MKO.⁶

Ambulant or home care exposure are scarcely published in literature as risk factor for MRSA carriage, as only ambulatory care facilities in Germany were described and designated as a reservoir for dissemination.²¹ Theoretically, transmission of MRSA

through ambulatory care could be possible, thus creating new MUO carriers. This finding necessitates further investigation in the future in The Netherlands, as ambulatory care facilities are becoming more important in a population with a growing segment of the elderly. The use of arbitrary cut-offs in risk factor definitions could theoretically result in MUO. However, after multivariate analysis we found no significant risk factors related to arbitrary cut-offs in risk factor definitions, such as 'less than two months ago' in case of a visit to a hospital abroad.

We could not confirm poultry consumption or scuba gear sharing as risk factors as found in the study by van Reijen et al.²² Possible explanations for the difference could be due to design, different selection and inclusion criteria of cases and controls, difference in questioning, and the number and selection of participating MML. Continuous analyses of MUO and its risk factors in the future will be necessary, not only to measure the effect of new policy implementation, but also to elucidate differences in outcome between studies. Two risk factors published in recent years, fine air particles for Cystic Fibrosis (CF) patients and livestock-density for livestock-associated MRSA, were not included in our case control questionnaire.^{23, 24} However, we think the impact of the absence of these risk factors in the questionnaire is minimal.

The use of standardized questionnaires, representative nationwide participation and community controls were study strengths which allows us to generalize results for all MUO in The Netherlands. Due to low national MRSA prevalence at hospital entry,¹ the odds of including MRSA carriers among the controls were very low. The confines of the MRSA surveillance database, the lack of exact data on infection/carriage, the necessity to contact and possible recall bias were limitations of our study. We aimed to enrol 500 cases and 1,000 controls based on an estimation of 700 MUO per two years to detect odds ratios of two or higher with 80% power. Inclusion of MUO was more difficult due to misclassification of some MUO and a lower willingness to participate in the study than expected. We therefore ended up including 232 cases and 667 controls, which was still enough to detect OR of 2 or higher with an 80% power and an alpha of 0.05, due to a larger number of controls per case. In the trawling questionnaire study, as well as in the case control study, we found there was misclassification of MKO as MUO, inflating the number of MUO in the MRSA surveillance. In the future, more effort is needed to detect the presence of risk factor before classifying a carrier as MUO, and thus registration of MKO or MUO in the RIVM database should be improved to reduce the number of misclassified MUO. Currently, 38% of total reported MRSA are reported as MUO^{3, 7}, underlining its significance. Even after correction for misclassification, MUO is estimated to be a fourth of total MRSA reported to the surveillance each year.

Some of the newly defined risk factors, such as antibiotic use, can be common (Table 2) and would have low specificity when included into S&D risk groups. Other risk factors, such as being part of contact tracing in the past, could result in changes to the national

guideline in regards to sampling frequency and timing. To determine the probability of MRSA carriage more precisely in the future, the known risk factors (current ones in the WIP guideline and from this study) should be analysed by creating risk tables or an algorithm. The presence of a single or combined risk factors could thus lead to targeted action such as screening or screening in combination with isolation on admission. Such a probability analysis could be subject of a next study.

For countries that apply a S&D approach as vertical infection prevention approach, MUO identification and elucidation is important. In a targeted screening approach as in S&D, persons at risk for MRSA carriage are identified (targeted) by means of risk factors. Monitoring MRSA is necessary to evaluate the effect of policy adjustments and any epidemiological changes that may give rise to new risk factors. Antibiotic use in the preceding 12 months, receiving ambulatory care and having at least one foreign parent, are common risk factors with limited practicality, but could still prove useful when combined to determine the probability of MRSA carriage risk based on a risk table and algorithm. In conclusion, risk factors for MUO were mainly healthcare related despite MUO carriers not always being hospital-associated. Our new risk factors elucidated 83% of MUO, bringing us a step closer to preventing MUO from undermining successful S&D policy.²⁵

ACKNOWLEDGMENTS

We would like to thank Arina Groenheide, Annelies van Ginkel, Yolanda van Weert, Dineke Frentz and Sjoukje Woudt for their supportive work in this study. Furthermore we would like to thank the participants, as well as the medical microbiologists, infection preventionists and other personnel of the following medical microbiological laboratories in The Netherlands that helped make this national study a success: Academic Medical Center, University of Amsterdam, Amsterdam, Admiraal de Ruyter Ziekenhuis, Goes/Vlissingen, ATAL-Medical Diagnostic Centre, Amsterdam, Atrium Medical Center Parkstad, Heerlen, Bronovo Hospital, The Hague, De Heel Zaans Medisch Centrum, Zaandam, Deventer Hospital, Deventer, Diaconessenhuis Leiden, Leiden, Diaconessenhuis Utrecht, Utrecht, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Gelderse Vallei Hospital, Ede, Gelre Hospital, Apeldoorn, Groene Hart Ziekenhuis, Gouda, Haga Hospital, The Hague, IJsselland Hospital, Capelle aan den IJssel, Ikazia Hospital, Rotterdam, Isala Klinieken, Zwolle, Jeroen Bosch Hospital, 's-Hertogenbosch, Laboratory for Infectious Diseases, Groningen, Laboratory for Pathology and Medical Microbiology (PAMM), Veldhoven, Laurentius Hospital, Roermond, Maasstad Hospital, Rotterdam, Maastricht University Medical Center, Maastricht, Medical Center Alkmaar, Alkmaar, Medical Center Leeuwarden, Izore Center for Infectious Diseases Friesland, Leeuwarden, Orbis Medical Center, Sittard-Geleen, Regional Public Health Laboratory Kennemerland, Haarlem,

Reinier de Graaf Groep, Delft, Rijnland Hospital, Leiderdorp, Rijnstate Hospital, Arnhem, SALTRO, Utrecht, SHL-group, Etten-Leur, Slingeland Hospital, Doetinchem, St. Antonius Hospital, Nieuwegein, St. Franciscus Gasthuis, Rotterdam, St. Jans Gasthuis, Weert, St. Jansdal Hospital, Harderwijk, Tergooi Hospitals Hilversum, Hilversum, UMC Utrecht, Utrecht, University Medical Center Groningen, Groningen, VieCuri Medical Center, Venlo, Vlietland Hospital, Schiedam, Westfries Gasthuis, Hoorn, Ziekenhuis Zeeuws- Vlaanderen, Terneuzen, Zuwe Hofpoort Hospital, Woerden, The Netherlands. This study was financed by ZonMw (125020010) and listed in the Dutch Trial Register (NTR2041). Data were presented at the International Symposium on Staphylococci and Staphylococcal infections 2016, Seoul, South Korea. Poster S01-02.

REFERENCES

1. Bode LG, Wertheim HF, Kluytmans JA, Bogaers-Hofman D, Vandenbroucke-Grauls CM, Roosendaal R, et al. Sustained low prevalence of methicillin-resistant *Staphylococcus aureus* upon admission to hospital in The Netherlands. *J Hosp Infect.* 2011; 79(3):198±201. <https://doi.org/10.1016/j.jhin.2011.05.009> PMID: 21763031
2. Paget J, Aangenend H, Kuhn M, Hautvast J, van Oorschot D, Olde Loohuis A, et al. MRSA Carriage in Community Outpatients: A Cross-Sectional Prevalence Study in a High-Density Livestock Farming Area along the Dutch-German Border. *PLoS One.* 2015; 10(11):e0139589. <https://doi.org/10.1371/journal.pone.0139589> PMID: 26619190
3. de Greeff SC MJ. *Nethmap / Maran 2017.* 2017.
4. Vos MC, Behrendt MD, Melles DC, Mollema FP, de Groot W, Parlevliet G, et al. 5 years of experience implementing a methicillin-resistant *Staphylococcus aureus* search and destroy policy at the largest university medical center in the Netherlands. *Infect Control Hosp Epidemiol.* 2009; 30(10):977±84. <https://doi.org/10.1086/605921> PMID: 19712031
5. Voss A, Loeffen F, Bakker J, Klaassen C, Wulf M. Methicillin-resistant *Staphylococcus aureus* in pig farming. *Emerg Infect Dis.* 2005; 11(12):1965±6. <https://doi.org/10.3201/eid1112.050428> PMID: 16485492
6. Lekkerkerk WS, van de Sande-Bruinsma N, van der Sande MA, Tjon ATA, Groenheide A, Haenen A, et al. Emergence of MRSA of unknown origin in the Netherlands. *Clin Microbiol Infect.* 2011.
7. Haenen A., Pluister G.N., van Luit M., Bosch T., Heck M.E.O.C., de Greeff S., et al. [Surveillance of MRSA in The Netherlands in 2011]2012 01 July 2013; 23(7). Available from: https://mrsa.rivm.nl/object_binary/o5177_MRSAverslag2011.pdf.
8. Dutch Workinggroup of Infection Prevention. WIP guideline MRSA: Werkgroep Infectiepreventie; 2012 [Available from: http://www.wip.nl/UK/disclaim.asp?url=http://www.wip.nl/UK/free_content/Richtlijnen/MRSA%20hospital.pdf].
9. Dutch Workinggroup of Infection Prevention. WIP guideline MRSA 2007 [Available from: http://www.wip.nl/UK/disclaim.asp?url=http://www.wip.nl/UK/free_content/Richtlijnen/MRSA%20hospital.pdf].
10. Soltani B, Taghavi Ardakani A, Moravveji A, Erami M, Haji Rezaei M, Moniri R, et al. Risk Factors for Methicillin Resistant *Staphylococcus aureus* Nasal Colonization of Healthy Children. *Jundishapur J Microbiol.* 2014; 7(9):e20025. <https://doi.org/10.5812/jjm.20025> PMID: 25485071
11. Lo WT, Lin WJ, Tseng MH, Wang SR, Chu ML, Wang CC. Risk factors and molecular analysis of panton-valentine leukocidin-positive methicillin-resistant *Staphylococcus aureus* colonization in healthy children. *Pediatr Infect Dis J.* 2008; 27(8):713±8. <https://doi.org/10.1097/INF.0b013e31816f63b5> PMID: 18600194
12. Miller M, Cook HA, Furuya EY, Bhat M, Lee MH, Vavagiakis P, et al. *Staphylococcus aureus* in the community: colonization versus infection. *PLoS One.* 2009; 4(8):e6708. <https://doi.org/10.1371/journal.pone.0006708> PMID: 19693269
13. Couderc C, Jolivet S, Thiebaut AC, Ligier C, Remy L, Alvarez AS, et al. Fluoroquinolone use is a risk factor for methicillin-resistant *Staphylococcus aureus* acquisition in long-term care facilities: a nested case-case-control study. *Clin Infect Dis.* 2014; 59(2):206±15. <https://doi.org/10.1093/cid/ciu236> PMID: 24729496

14. Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant *Staphylococcus aureus* (MRSA) isolation? A systematic review and meta-analysis. *J Antimicrob Chemother.* 2008; 61(1):26±38. <https://doi.org/10.1093/jac/dkm416> PMID: 17986491
15. Central Bureau for Statistics (CBS). Within Europe least antibiotics provided in The Netherlands [Binnen Europa in Nederland minste antibiotica verstrekt]: CBS; 2016 [Available from: <https://www.cbs.nl/nl-nl/nieuws/2016/06/binnen-europa-in-nederland-minste-antibiotica-verstrekt>].
16. Lekkerkerk WS, Uljee M, Prkic A, Maas BD, Severin JA, Vos MC. Follow-up cultures for MRSA after eradication therapy: Are three culture-sets enough? *J Infect.* 2015.
17. Larsen AR, Bocher S, Stegger M, Goering R, Pallesen LV, Skov R. Epidemiology of European community-associated methicillin-resistant *Staphylococcus aureus* clonal complex 80 type IV strains isolated in Denmark from 1993 to 2004. *J Clin Microbiol.* 2008; 46(1):62±8. <https://doi.org/10.1128/JCM.01381-07> PMID: 17989197
18. Ravensbergen SJ, Berends M, Stienstra Y, Ott A. High prevalence of MRSA and ESBL among asylum seekers in the Netherlands. *PLoS One.* 2017; 12(4):e0176481. <https://doi.org/10.1371/journal.pone.0176481> PMID: 28441421
19. Reinheimer C, Kempf VA, Gottig S, Hogardt M, Wichelhaus TA, O'Rourke F, et al. Multidrug-resistant organisms detected in refugee patients admitted to a University Hospital, Germany June December 2015. *Euro Surveill.* 2016; 21(2).
20. RIVM. [HRMO and MRSA screening and isolation policy for highrisk patient populations from abroad.] BRMO- en MRSA- screenings- en isolatiebeleid voor hoogrisicopatieëntenpopulaties vanuit het buitenland.:RIVM; 2016 [updated 08-11-2016. Available from: http://www.rivm.nl/Documenten_en_publicaties/Algemeen_Actueel/Uitgaven/Infectieziekten_Bulletin/Jaargang_27_2016/November_2016/Inhoud_november_2016/BRMO_en_MRSA_screenings_en_isolatiebeleid_voor_hoogrisico_pati_ntenpopulaties_vanuit_het_buitenland].
21. Gruber I, Heudorf U, Werner G, Pfeifer Y, Imirzalioglu C, Ackermann H, et al. Multidrug-resistant bacteria in geriatric clinics, nursing homes, and ambulant care: prevalence and risk factors. *Int J Med Microbiol.* 2013; 303(8):405±9. <https://doi.org/10.1016/j.ijmm.2013.05.002> PMID: 23770266
22. van Rijen MM, Kluytmans-van den Bergh MF, Verkade EJ, Ten Ham PB, Feingold BJ, Kluytmans JA, et al. Lifestyle-Associated Risk Factors for Community-Acquired Methicillin-Resistant Carriage in the Netherlands: An Exploratory Hospital-Based Case-Control Study. *PLoS One.* 2013; 8(6):e65594. <https://doi.org/10.1371/journal.pone.0065594> PMID: 23840344
23. Davies PR, Alexander BH, Bender JB, Deen J, Dewey CE, Funk JA, et al. Livestock density as risk factor for livestock-associated methicillin-resistant *Staphylococcus aureus*, The Netherlands. *Emerg Infect Dis.* 2013; 19(9):1551±2. <https://doi.org/10.3201/eid1909.130876> PMID: 23968678
24. Psoter KJ, De Roos AJ, Wakefield J, Mayer JD, Rosenfeld M. Air pollution exposure is associated with MRSA acquisition in young U.S. children with cystic fibrosis. *BMC Pulm Med.* 2017; 17(1):106. <https://doi.org/10.1186/s12890-017-0449-8> PMID: 28750627
25. Boucher HW, Corey GR. Epidemiology of methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis.* 2008; 46 Suppl 5:S344±9.

SUPPLEMENTARY LIST 1

CASE CONTROL QUESTIONNAIRE

0. Date of filling out the questionnaire

General

1. What is your sex?
2. What is your birthdate?
3. What is your postal code? (4 out of 6 characters)
4. a. What is your country of birth?
b. If you were born outside the Netherlands, were you adopted?
5. In which country were your parents born?
6. a. Did you move the last two years?
b. If yes, what was your previous postal code? (4 out of 6 characters)
7. What is your sexual preference?
8. In your household, are you the one who regularly cooks?
9. Do you wash your hands when preparing the food?
10. a. Are you vegetarian?
b. If no, do you eat raw meat?
11. Do you visit one of the following locations? (Swimming pool, beach/sea, river/lake, sauna, whirlpool, pedicure, beauty salon)
12. Did you have a tattoo or piercing in the last twelve months?

Household

13. How many people are in your household?
14. Which of the following objects do you regularly share among your household members? (towels, wash cloths, bedsheets, shaving razors, toothbrushes, combs, creams, other, none)
15. Was someone in your household hospitalized the last year?

MRSA

16. a. Have you ever been MRSA positive?
b. In the last twelve months?
c. Do you know the exact period?
d. Who detected the MRSA? (Hospital, long term care facility, general practitioner, other)
17. a. Have you ever been treated against MRSA with an 'eradication therapy'?
b. Did this get rid of the MRSA?
c. During eradication therapy, were your household members screened?
d. Were they also treated?

General health

18. a. Do you sport?
b. What type of sport? (team, individual, contact, with animals)
19. Do you smoke?
20. a. Do you dialyze?
b. If so, have you been dialyzed abroad?
21. a. Do you know if you have/had contact with a MRSA carrier?
b. If so, where did you have contact with this MRSA carrier?
c. If elsewhere, where exactly?
d. What was your relation compared to this MRSA carrier?
e. Do you have close contact with certain people? (inside the household, outside or with people from inside and outside the household)
22. a. Have you ever been contacted in regards to contact tracing for another MRSA carrier?
b. Were you then found to be MRSA positive?
23. a. Did you use antibiotics in the last twelve months?
b. If so, how often and when?
c. If so, do you remember the names?
24. a. Do you have a skin disease diagnosed by a doctor?
b. If so, is this eczema?
25. a. Do you have a chronic disease?
b. If so, to which group does your chronic disease belong? (lungs, cardiac/heart, auto-immune, other metabolic, diabetes, chronic infection, congenital, other, don't know)
c. Do you happen to know the name of your chronic disease?
d. Do you use immunosuppressive medications?
e. If so, do you remember the names of these medications?
26. a. Did you receive ambulant care the last two years?
b. If so, how often?
c. If so, which kind? (homecare, general practitioner, mental healthcare, obstetric

care, maternity, supervised living, physiotherapy, dispensary, other)

27. Did you visit an outpatient department of a Dutch hospital in the last twelve months?
28. Were you admitted to a Dutch hospital or nursing home in the last twelve months?
29. Were you care for on a department in a Dutch hospital or nursing home in the last twelve months where there was a known MRSA outbreak?
30. Did you come into contact with a MRSA carrier in a Dutch hospital or nursing home?

Work

31. Which situation applies to you? (Employed, retired, standing entrepreneur, student, jobless, going to school, volunteer job, <4 years old)
32. In which sector do/did you work? (Healthcare, animals, shipping, other)
33. In which sector does/did your partner work? (healthcare, animals, shipping, other)
34. In which sector does/did your household members work? (healthcare, animals, shipping, other)

Following questions only for those working in healthcare

35. a. Have you come into contact with a MRSA carrier?
- b. Did you take infection prevention precautions?
- c. Was MRSA detected at you after you had contact with a MRSA carrier?
36. Did you accompany patients in the last twelve months when they were transferred from a hospital abroad to one in the Netherlands? (Or the other way around)

Animal Contact

37. a. Did you have contact with pigs or veal calves outside your work?
- b. If yes, with pigs, veal calves or both?
- c. Where did you come into contact with these animals?
38. a. Did you partner or one of your household members come into contact with pigs or veal calves outside work?
- b. If yes, where did they come into contact with these animals?
39. a. Do you keep pets or farm animals?
- b. If so, which ones?
40. Do you ride or take care of horses?
41. Do you visit farms or petting zoos?

Abroad

42. a. Have you been abroad the previous year?
- b. If so, please name the countries you travelled to in your last five trips abroad within a maximum timespan of two years. And whether or not you visited a hospital then.
- c. If you visit a hospital abroad in the last two years, what was the reason? (Visit a patient, small surgery, outpatient clinic visit, admitted to hospital as patient, for work, other)
- d. Did you become MRSA positive after your visit to an abroad hospital in the last two years?
- e. Did you visit a Dutch hospital after your abroad hospital visit?
- f. Have you ever been in an abroad hospital?
43. a. Did a household or family member become MRSA positive after an abroad hospital visit? (in the last two years)
- b. Has a household or family member been to a Dutch hospital after visit an abroad hospital? (in the last two years)
- c. Has a household or family member ever been to an abroad hospital?